Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial

NCT02850965 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02850965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02850965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
August 17, 2016
Completion date
January 17, 2018
Enrollment
318 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis